The
global flow cytometry market is expected to reach USD 4.79 billion by 2022 from
USD 3.29 billion in 2017 growing at a CAGR of 7.8% during forecast period. Factors
such as continuous technological advancements in the field of flow cytometry, prevalence of target diseases (such as HIV/AIDS
and cancer), growing adoption of flow cytometry in advanced research activities
and clinical trials, and the increasing availability of novel
application-specific flow cytometry products are driving the growth of the flow
cytometry market.
Strategic
analysis of the market developments between 2014 and 2017 revealed that several
growth strategies such as product launches, enhancements, acquisitions, partnerships,
collaborations, and expansions were adopted by the market players to strengthen
their product portfolios and maintain a competitive position in the flow
cytometry market. Among these business strategies, product launches and enhancements,
partnerships, and collaborations were the most widely adopted growth strategies
by the players in this market.
Becton,
Dickinson and Company (US) held the leading position in the global flow
cytometry market in 2016. The company offers a comprehensive range of solutions
for flow cytometry-based cell analysis and cell sorting. BD has a broad and
balanced geographic footprint through offices located in more than 50 countries,
which maximizes marketing opportunities for its products. The company adopts
both organic (product development and launches) and inorganic growth strategies
(such as collaborations, partnerships, and acquisitions) which help it strengthen its position and increase
its revenue base in the flow cytometry market. For instance, in last three
years, the company launched several flow cytometry products, such as BD Precise
whole transcriptome analysis (WTA) reagents, BD FACSPresto CD4/Hb Cartridge, BD
FACSLyric, BD FACSVia, BD FACSMelody, BD FACSymphony, BD FACSCelesta, and BD
FACSPresto flow cytometer systems. In addition,
BD also entered into various collaborations & partnerships to enhance its
R&D capabilities.
Beckman
Coulter (US) is another major player in the flow cytometry market in 2016. The
company is focused on strengthening its
market position in the global flow cytometry market mainly by adopting the
strategies such as product launches, agreements, collaboration, and
acquisitions. For instance in the past few years, the company acquired Xitogen
Technologies, Inc. (China) to strengthen its product R&D and manufacturing
activities; entered into a distribution agreement with IncellDx, Inc. (US); and
collaborated with Genera Biosystems Limited (Australia). The company also launched
a few innovative products in the past three years, such as ClearLLab LS lymphoid screen reagents, CytoFLEX
Flow cytometer, and Aquios CL clinical flow cytometer.
To Know More @
No comments:
Post a Comment